Lynn Kirkpatrick
Tracked across 4 events · 24 articles · First seen Jun 26, 2026 · Last active Sep 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Lynn Kirkpatrick, as CEO of Altor BioScience, provided key statements regarding the significance of the PF614-MPAR technology in addressing the opioid crisis and establishing a new standard for opioid safety.
Jun 26, 2026 · 6 articles
Tech
Impact: As CEO, Lynn Kirkpatrick is a featured speaker and spokesperson, representing the company's leadership in the symposium.
Aug 20, 2026 · 6 articles
Business
Impact: As CEO, Lynn Kirkpatrick is the public face of the announcement and her leadership is central to the company's progress. The event reflects positively on her management.
Aug 31, 2026 · 6 articles
Business
Impact: Lynn Kirkpatrick is the CEO of Ensysce and is listed as a company contact; her role is unchanged.
Sep 02, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Lynn Kirkpatrick live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard